LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

Home・Akciju saraksts・Cogent Biosciences Inc

Cogent Biosciences Inc

Slēgts

37.06 -4.66

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

36.28

Max

37.94

Galvenie mērījumi
By Trading Economics
Ienākumi	-22M -102M
EPS	-0.5
Darbinieki	258
EBITDA	-30M -109M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+34.17% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	408M 6B
Iepriekšējā atvēršanas cena	41.72
Iepriekšējā slēgšanas cena	37.06

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

4.88 / 5.87 Atbalsts un pretestība

Cogent Biosciences Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 3. marts 18:43 UTC

Galvenie ziņu notikumi

Fed's Kashkari Says Too Soon To Know Inflation Impact From Middle East Conflict

2026. g. 3. marts 17:33 UTC

Iegādes, apvienošanās, pārņemšana

Ziff Davis to Sell Connectivity Division to Accenture for $1.2 Billion -- Update

2026. g. 3. marts 23:45 UTC

Tirgus saruna

Nikkei May Fall on Continued Concerns About Energy Costs -- Market Talk

2026. g. 3. marts 23:44 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Rises on Possible Dip-Buying Amid Ongoing Middle East Conflict -- Market Talk

2026. g. 3. marts 23:25 UTC

Tirgus saruna

Bannerman Energy Likely to Raise Less Equity for Uranium Projects -- Market Talk

2026. g. 3. marts 23:25 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2026. g. 3. marts 22:38 UTC

Galvenie ziņu notikumi

Iran Conflict Pushes Europe Toward Fresh Energy Crisis -- WSJ

2026. g. 3. marts 22:16 UTC

Peļņas

Berkshire Provides Scant Fourth-Quarter Financials. Investors Need to Do Their Own Calculations. -- Barrons.com

2026. g. 3. marts 22:09 UTC

Peļņas

Century Aluminum Changed Historical Method of Proportionately Consolidating Jamalco Production Assets to a Full Consolidation

2026. g. 3. marts 22:06 UTC

Peļņas

Century Aluminum: Accounting Change for 2023 and 2024 Doesn't Impact Net Income Attributable to Century Stockholders

2026. g. 3. marts 22:05 UTC

Peļņas

Century Aluminum Initially Concluded That an Accounting Change Was Immaterial, SEC Staff Disagreed With Company's Materiality Conclusion

2026. g. 3. marts 22:03 UTC

Peļņas

Century Aluminum to Restate Certain Results in Connection Wtih Accounting Change for Jamalco

2026. g. 3. marts 21:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Tech, Media & Telecom Roundup: Market Talk

2026. g. 3. marts 21:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 3. marts 21:45 UTC

Galvenie ziņu notikumi

The Iran War Puts the Fed's Rate-Cut Timeline in Doubt -- Barrons.com

2026. g. 3. marts 21:37 UTC

Peļņas

EVgo Stock Rises as Earnings Defy EV Slump. The Rest of 2026 Doesn't Look So Rosy. -- Barrons.com

2026. g. 3. marts 21:26 UTC

Galvenie ziņu notikumi

Freeport McMoRan Stock Slides as the Mideast Conflict Hits Commodities -- Barrons.com

2026. g. 3. marts 20:31 UTC

Tirgus saruna

Galvenie ziņu notikumi

U.S. Natural Gas Gains on Middle East Turmoil, Weather Outlook -- Market Talk

2026. g. 3. marts 20:04 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Pull Back as Trump Offers Shipping Protection -- Market Talk

2026. g. 3. marts 19:17 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold and Silver Drop as Energy Surges -- Market Talk

2026. g. 3. marts 18:43 UTC

Peļņas

Berkshire CEO Abel Is Fond of Financial Metric Similar to One Criticized by Buffett -- Barrons.com

2026. g. 3. marts 18:29 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Energy Roundup: Market Talk

2026. g. 3. marts 18:29 UTC

Tirgus saruna

Galvenie ziņu notikumi

Norsk Hydro Announces Stoppage of Qatar Aluminum Smelter -- Market Talk

2026. g. 3. marts 18:22 UTC

Galvenie ziņu notikumi

Fed's Kashkari on March Projections: Had a Lot of Confidence Up Until a Few Days Ago

2026. g. 3. marts 18:22 UTC

Galvenie ziņu notikumi

Fed's Kashkari: Too Soon to Know Impact Iran Conflict Will Have on Inflation

2026. g. 3. marts 18:17 UTC

Tirgus saruna

Galvenie ziņu notikumi

Strait of Hormuz Standstill Keeps Bid in Oil Futures -- Market Talk

2026. g. 3. marts 18:14 UTC

Peļņas

How Long Can Anthropic Play Defense? -- WSJ

2026. g. 3. marts 17:41 UTC

Galvenie ziņu notikumi

Exxon Is Down Since the Iran Conflict. These Energy Stocks Are Bigger Winners. -- Barrons.com

2026. g. 3. marts 17:36 UTC

Galvenie ziņu notikumi

Iran Conflict is Starting to Boost Gasoline Prices -- Update

2026. g. 3. marts 17:28 UTC

Iegādes, apvienošanās, pārņemšana

Tinicum, Blackstone to Make Decision on Offer By End of Day March 31

Salīdzinājums

Cenas izmaiņa

Cogent Biosciences Inc Prognoze

Cenas mērķis

By TipRanks

34.17% augšup

Prognoze 12 mēnešiem

Vidējais 52.18 USD 34.17%

Augstākais 67 USD

Zemākais 35 USD

Pamatojoties uz 12 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Cogent Biosciences Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

12 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 12 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Cogent Biosciences Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

4.88 / 5.87Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.